Spark Therapeutics Inc(NASDAQ:ONCE) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-Market on Feb 22, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $1.303M. Analysts estimated a revenue of $2.640M. The revenues were -50.64% below the estimates. Earnings per share were $-1.21. The reported EPS was below estimates by -8.04%. Analysts had estimated an EPS of $-1.12.
In a different note, Leerink Swann said it Initiates Coverage On Spark Therapeutics Inc, according to a research note issued on Feb 9, 2017. In the research note, the firm Announces the price-target to $85 per share. The shares have been rated ‘Outperform’ by the firm. BMO Capital said it Initiates Coverage On Spark Therapeutics Inc, according to a research note issued on Dec 20, 2016. In the research note, the firm Announces the price-target to $69 per share. The shares have been rated ‘Outperform’ by the firm.
Spark Therapeutics Inc (ONCE) shares turned negative on Wednesdays trading session with the shares closing down -3.33 points or -5.15% at a volume of 6,68,823. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $64.7. The peak price level was also seen at $64.7 while the days lowest was $59.53. Finally the shares closed at $61.38. The 52-week high of the shares is $65.99 while the 52-week low is $28.3815. According to the latest information available, the market cap of the company is $1,889 M.
Several Insider Transactions has been reported to the SEC. On Feb 16, 2017, Anand Mehra (director) sold 35,347 shares at $65.02 per share price.Also, On Dec 16, 2016, Barge Joseph La (officer ) sold 3,000 shares at $53.31 per share price.On Nov 16, 2016, Katherine A High (director officer ) sold 10,000 shares at $60.30 per share price, according to the Form-4 filing with the securities and exchange commission.
Spark Therapeutics Inc. (Spark) is engaged in developing products in the field of gene therapy. Spark’s product candidate SPK-RPE65 which is in Phase III clinical trial stage targets a group of rare blinding conditions known as inherited retinal dystrophies (IRDs) caused by non-sex linked or autosomal recessive mutations in the RPE65 gene. Spark is also developing various follow-on product candidates targeting other IRDs including SPK-CHM for the treatment of choroideremia (CHM). SPK-CHM is in Phase I/II dose-escalating clinical trial stage. The Company’s product development portfolio includes product candidates targeting expression of genes in the liver with a focus on hematologic disorders. The Company is also engaged in the development and commercialization of product candidates in its SPK-FIX program for the treatment of hemophilia B. Spark also has preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases.